This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Good luck you guys a lot of you deserve it for sticking with it.
I wrongly fell in love with this share but bailed when it got to my break even point.
If i was still in and this got to 3.00 again i don`t think i would have the nerve to keep holding after what happened last time.
Good Luck
DB66

Hi mickeyskint,
anywhere could find out more about 'Note issued by JM Finn with a target price of 435p'? Thanks

swseun

I just picked it up from an other board so I can't really add much more, other that JM Finn don't have the best reputation in the world. So it could be rubbish. I feel sure that we will see new highs when a deal is done. So untill then we just have to be patience.

LOL
MS

Thanks MS,

I temp to top up but wonder if the price would go back down. Coz it happened quite often at this price level. and yes, right now, be patience is the only choice to me. :-)

Expecting 180p short term not sure about the 435p target .

Stiil its >>>>>>>>>>> NICE.

Flying again.

Somebody mentions a broker note out of 4 plus over the road.

Dont know if its been verified.

I think mitzy could be right re 180

MS

Yup and more.

Some comment in Fridays Mail re positive brokers note due.

MMG practised its boring sideway between 120p to 200p for about 1.5 years. This period should be long enough to shake out the investors who find bored, so once if MMG rise, it will be big.

swseun

Well its back into the blue today.

Moving up nicely.

From the other side.

everton448 - 5 Feb'07 - 14:15 - 8002 of 8003


Not sure if this has been posted before - taken from a post on the interactive investor website - it purports to be an extract from the Finn buy note


"The valuation of any young company such as MMI is a challenging task. MMI is moving towards the next major development phase. In our July note we indicated a conservative price target of 250p based on the mid-point marker value of companies in the cancer vaccine arena: Cell Genesys (GEGE US), Cerus (CERS US), Dendreon (DNDN US), Genitope (GTOP US) and Oxford Biomedica (OXB LN).

This gave at the time an approximate market value between 110m and 190m, after making a proportional adjustment to take into consideration the MMI ownership of DNA vaccines and chemotherapies and excluded rybozymes.

The preclinical development progress made in the last few months and the ever increasing news flow emerging from the relentless M&A and licensing activity in the industry have greatly de-risked MMIs approach. Given the fact that there are no listed direct comparable companies in terms of the technology platforms covered by MMI we have decided to value MMI using a discounted P/E multiple analysis and not to use a discounted cash flow due to the current difficulty in accurately forecasting MMIs future revenues and earning given the lack of clarity on the licensing pattern.

Our fair value for the share is 435p and we arrive at this price by applying a 25x PER multiple to our estimated 2008 EPS forecast of 25.3p discounted back to the present time by 35%. We believe that a 25 multiple would be typical for a young company just achieving profitability. The 35% discount represents our broad estimation of the continuing risks associated with achieving our forecasts and, by implication, the development milestone we have described elsewhere in this note"

mickeyskint,
what do you think about the 'conservative price target of 250p ....Our fair value for the share is 435p.'?

have been wait for 2 years!!! Time to come!!

swseun

435p, blimey Ill take that.

Its on its way to 435p...........NICE.

On the way up lets hope it can hold it's gains. It went past 250 a couple of years ago so I don't think 435 is unrealistic if they have a tie up with one of the majors.

MS

GF
If you fancy a 60/40 punt have a look at FRR, Could be all or nothing.

Good News!!

Medical Marketing Int'l Group PLC
09 February 2007

Notification of Major Interests in Shares
9 February 2007

Medical Marketing International Group plc (the 'Company')(AIM:MMG), the
pharmaceutical company focused on the development of drugs for cancer and
infectious diseases, received notification on 8 February 2007 that Man Financial
Limited is interested in 3,039,200 ordinary shares of 0.2p each of the Company;
this represents 5.18% of the Company's issued share capital of 58,637,671
ordinary shares.
-ends-

Contacts
Medical Marketing International Group plc
David Best
Executive Chairman
Rob Sprawson
Chief Financial Officer
Tel: +44 (0) 1223 477 677

About MMI Group

MMI is a virtual pharmaceutical development company that identifies, acquires
and develops world-class compounds and technologies from leading academic
organizations. These technologies are aimed at producing blockbuster drugs to
satisfy unmet needs in major therapeutic markets. The company manages the
preclinical and early clinical development of drug candidates before pursuing
licensing partners to manage late-stage development. Through its three platform
technologies MMI has a risk-balanced portfolio of compounds in development for
the treatment of cancer and infectious disease. Please visit
www.mmigroup.co.uk

for further information.

Price should be up very soon.

Could we be on the move to 200. Lets hope so.

MS